Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
48.44
-0.02 (-0.04%)
Aug 13, 2025, 2:56 PM - Market open
EngageSmart Revenue
Praxis Precision Medicines had revenue of $7.77M in the twelve months ending June 30, 2025, up 338.45% year-over-year. In the year 2024, Praxis Precision Medicines had annual revenue of $8.55M with 249.53% growth.
Revenue (ttm)
$7.77M
Revenue Growth
+338.45%
P/S Ratio
127.05
Revenue / Employee
$66,940
Employees
116
Market Cap
1.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.55M | 6.11M | 249.53% |
| Dec 31, 2023 | 2.45M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PRAX News
- 6 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Praxis Precision Medicines to Participate in Upcoming Fireside Chat - GlobeNewsWire
- 7 days ago - Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewsWire
- 9 days ago - Praxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 27 days ago - Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies - GlobeNewsWire
- 3 months ago - Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Benzinga
- 3 months ago - Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire